Evidence map›Paper›PMID 28592183›Full record

ArticlePharmaceutical development and technology2018

Vaginal film for prevention of HIV: using visual and tactile evaluations among potential users to inform product design.

K M Guthrie, L Rohan, R K Rosen, S E Vargas, J G Shaw, D Katz, E M Kojic, A S Ham, D Friend, K W Buckheit and 1 more

Registry-linked trialAbstract read
In one paragraph

Article in Pharmaceutical development and technology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06046053 (MATRIX-002), which is not on this map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06046053 early_phase1completednot on this mapstarted 2023, after this paper: background citation

MATRIX-002: Trial to Assess Acceptability and Safety of Two Placebo Prototype Vaginal Films

TypeinterventionalSponsorRohan, Lisa, PhDRan2023 to 2024Enrolled100ConditionsSafety, Acceptability, UsabilityArmsPlacebo Vaginal Film with Square Corners, Placebo Vaginal Film with Rounded Corners
3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Trial
  2. Article
  3. Vaginal Sheets withGels (Basel, Switzerland) · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

K M Guthriea Centers for Behavioral and Preventive Medicine , The Miriam Hospital , Providence , RI , USA.ORCID http://orcid.org/0000-0002-5528-1212
L Rohand Magee-Womens Research Institute , Pittsburgh , PA , USA.
R K Rosena Centers for Behavioral and Preventive Medicine , The Miriam Hospital , Providence , RI , USA.
S E Vargasa Centers for Behavioral and Preventive Medicine , The Miriam Hospital , Providence , RI , USA.
J G Shawa Centers for Behavioral and Preventive Medicine , The Miriam Hospital , Providence , RI , USA.
D Katzf Biomedical Engineering and Obstetrics/Gynecology, Duke University , Durham , NC , USA.
E M Kojicg Division of Immunology , The Miriam Hospital , Providence , RI , USA.
A S Hamh ImQuest BioSciences, Inc , Frederick , MD , USA.
D Friendi CONRAD , Arlington , VA , USA.
K W Buckheith ImQuest BioSciences, Inc , Frederick , MD , USA.
R W Buckheith ImQuest BioSciences, Inc , Frederick , MD , USA.

Funding

Scientific CoreU19AI101961 · NIAID · IMQUEST BIOSCIENCES · PI KATZ, DAVID FRANK · 2012 to 2016
$14.3M
Pharmaceutical and Regulatory CoreU19AI082639 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI HILLIER, SHARON L. · 2010 to 2014
$13.0M
Rational Development of Combination Microbicide TherapiesR33AI076967 · NIAID · IMQUEST BIOSCIENCES · PI BUCKHEIT, ROBERT WALTER · 2008 to 2010
$1.4M
NIAID NIH HHS R33 AI076967NIAID NIH HHS U19 AI082639NIAID NIH HHS U19 AI101961
6 · The paper itself

Abstract

Topical prevention of HIV and other STIs is a global health priority. To provide options for users, developers have worked to design safe, effective and acceptable vaginal dissolving film formulations. We aimed to characterize user experiences of vaginal film size, texture and color, and their role in product-elicited sensory perceptions (i.e. perceptibility), acceptability and willingness to use. In the context of a user-centered product evaluation study, we elicited users' 'first impressions' of various vaginal film formulation designs via visual and tactile prototype inspection during a qualitative user evaluation interview. Twenty-four women evaluated prototypes. Participants considered size and texture to be important for easy insertion. Color was more important following dissolution than prior to insertion. When asked to combine and balance all properties to arrive at an ideal film, previously stated priorities for individual characteristics sometimes shifted, with the salience of some individual characteristics lessening when multiple characteristics were weighted in combination. While first impressions alone may not drive product uptake, users' willingness to initially try a product is likely impacted by such impressions. Developers should consider potential users' experiences and preferences in vaginal film design. This user-focused approach is useful for characterizing user sensory perceptions and experiences relevant to early design of prevention technologies.

Indexed as

Administration, IntravaginalAnti-HIV AgentsAnti-Infective Agents, LocalChemistry, PharmaceuticalFemaleHIV InfectionsHumansMaleSexually Transmitted DiseasesVaginal Creams, Foams, and JelliesAnti-HIV AgentsAnti-Infective Agents, LocalVaginal Creams, Foams, and JelliesHIV preventioninitial acceptabilitymultipurpose prevention technologiesperceptibilityuser-centered product designVaginal film

Identifiers

PMID28592183
PMCPMC5740013

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.